1. Home
  2. ENTA vs NBB Comparison

ENTA vs NBB Comparison

Compare ENTA & NBB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$12.50

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Logo Nuveen Taxable Municipal Income Fund of Beneficial Interest

NBB

Nuveen Taxable Municipal Income Fund of Beneficial Interest

HOLD

Current Price

$15.67

Market Cap

446.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
NBB
Founded
1995
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
446.2M
IPO Year
2012
2010

Fundamental Metrics

Financial Performance
Metric
ENTA
NBB
Price
$12.50
$15.67
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.40
N/A
AVG Volume (30 Days)
143.3K
58.0K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
N/A
Revenue This Year
$7.76
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$14.52
52 Week High
$17.15
$16.62

Technical Indicators

Market Signals
Indicator
ENTA
NBB
Relative Strength Index (RSI) 44.54 49.96
Support Level $12.09 $15.47
Resistance Level $15.52 $15.99
Average True Range (ATR) 0.78 0.24
MACD -0.07 -0.01
Stochastic Oscillator 36.00 80.65

Price Performance

Historical Comparison
ENTA
NBB

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About NBB Nuveen Taxable Municipal Income Fund of Beneficial Interest

Nuveen Taxable Municipal Income Fund is a closed-end fund incorporated in the United States. Its primary objective is current income through investments in taxable municipal securities; the secondary objective is to seek enhanced portfolio value and total return. The fund invests a majority of its assets in a diversified portfolio of taxable municipal securities.

Share on Social Networks: